You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 47 Baseline blood DNA methylation-based immune profiles and tumor mutational burden predict survival outcomes in anti-PD-1 treated head and neck cancer patient

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
47 Baseline blood DNA methylation-based immune profiles and tumor mutational burden predict survival outcomes in anti-PD-1 treated head and neck cancer patient

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zhang Z, Sehgal K, Shirai K, et al
47 Baseline blood DNA methylation-based immune profiles and tumor mutational burden predict survival outcomes in anti-PD-1 treated head and neck cancer patient
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0047